Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-05-2007 | Laboratory Investigation

The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia

Authors: Nurit Mathalone, Nitza Lahat, Michal A. Rahat, Keren Bahar-Shany, Yoram Oron, Orna Geyer

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2007

Abstract

Background

The involvement of matrix metalloproteinases (MMPs) in ischemic tissue damage and remodeling has been reported by many investigators. Our study was designed to investigate the involvement of MMPs and of tissue inhibitors of metalloproteinases (TIMPs) in rat retinal ischemic injury, the effect of nitric oxide synthase (NOS) inhibitors on MMPs’ activity in this model and whether minocycline (an MMP inhibitor) is protective in retinal ischemia.

Methods

Ninety-four rats were used in the study. Ischemia was induced by 90 min elevation of intraocular pressure. MMPs’ activities and the effect of NOS inhibitors [aminoguanidine (AG) or N-nitro-L-arginine (NNA)] and minocycline on MMPs’ activities were assessed by zymography and TIMPs expression by Western analysis. Morphological damage was quantified by morphometry of hematoxylin and eosin-stained retinal sections.

Results

Retinal extracts exhibited activities of proMMP-9 and proMMP-2. The activity of proMMP-9 increased immediately post ischemia (PI) and peaked to 4.6 times that of normal untreated controls in ischemic retinas and to 2.6 times that of controls in retinas of fellow sham-treated eyes at 24 h PI. The relative amount of TIMP-1 increased to 1.9-fold following ischemia and 2.5-fold in fellow sham-treated eyes at 24 h PI. ProMMP-2 activity increased more than two-fold immediately, at 24 h and at 48 h PI in ischemic retinas, and insignificantly in fellow sham-treated eyes. Treatment with 25 mg/kg AG or NNA caused a non-significant increase in proMMP-9 activity at 24 h PI (3.7- and 2.9-fold, respectively, p>0.6). There was no effect of AG or NNA on the activity of proMMP-2. Minocycline significantly attenuated the retinal ischemic damage, primarily by partially preserving ganglion cells and the inner plexiform layer. Minocyline (0.5 mg/ml or 5 mg/ml) inhibited MMPs’ activities in ischemic retinal extracts in vitro.

Conclusions

MMPs participated in morphological ischemic damage to rat retina. Treatment with minocycline dramatically attenuated damage to the retina.

Adachi K, Fujita Y, Morizane C, Akaike A, Ueda M, Satoh M, Masai H, Kashii S, Honda Y (1998) Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur J Pharmacol 350:53–57PubMedCrossRef

Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME (2004) An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol 66:1113–1122PubMedCrossRef

Belayev L, Busto R, Zhao W, Ginsberg MD (1996) Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 739:88–96PubMedCrossRef

Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potent therapy for multiple sclerosis. Brain 125:1297–1308PubMedCrossRef

Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase -3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797–801PubMedCrossRef

Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schultz R (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101:1833–1839PubMed

Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53–56PubMedCrossRef

Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, Bottero V, Anglard P, Yiotakis A, Dive V, Gugenheim J, Auberger P (2002) Rat liver injury after nonthermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J 16:93–95PubMed

D’Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35:3974–3979PubMed

10.

Das A, McLamore A, Song W, Mcguire PG (1999) Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117:498–503PubMed

11.

Duivenvoorden WC, Hirte HW, Singh G (1997) Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 17:312–322PubMed

12.

Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842:92–100PubMedCrossRef

13.

Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19:1020–1028PubMedCrossRef

14.

Geyer O, Almog J, Lupu-Meiri M, Lazar M, Oron Y (1995) Nitric oxide synthase inhibitors protect rat retina against ischemic injury. FEBS Lett 374:399–402PubMedCrossRef

15.

Hangai M, Miyamoto K, Hiroi K, Tujikawa A, Ogura Y, Honda Y, Yoshimura N (1999) Roles of constitutive nitric oxide synthase in postischemia rat retina. Invest Ophthalmol Vis Sci 40:450–458PubMed

16.

Horton WE Jr, Udo I, Precht P, Balakir R, Hasty K (1998) Cytokine inducible matrix metalloproteinase expression in immortalized rat chondrocytes is independent of nitric oxide stimulation. In Vitro Cell Dev Biol Anim 34:378–384PubMed

17.

Jain S, Bicknell GR, Nicholson ML (2000) Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg 87:1188–1192PubMedCrossRef

18.

Jiang X, Namura S, Nagata I (2001) Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 305:41–44PubMedCrossRef

19.

Ju W, Kim K, Park D, Park C, Oh S, Chung J, Chum M (2000) Nitric oxide is involved in sustained and delayed cell death of rat retina following transient ischemia. Brain Res 881:231–236PubMedCrossRef

20.

Kosano H, Okano T, Katsura Y, Noritake M, Kado S, Matsuoka T, Nishigori H (1999) ProMMP-9 (92 KDa) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64:2307–2315PubMedCrossRef

21.

Lahat N, Rahat MA, Brod V, Cohen S, Weber G, Kinarty A, Bitterman H (1999) Abdominal surgery reduces the ability of rat spleen cells to synthesize and secrete active TNF-α by a multilevel regulation. Clin Exp Immunol 115:19–25PubMedCrossRef

22.

Ledingham MA, Denison FC, Riley SC, Norman JE (1999) Matrix metalloproteinase-2 and -9 and their inhibitors are produced by the human uterine cervix but their secretion is not regulated by nitric oxide donors. Hum Reprod 14:2089–2096PubMedCrossRef

23.

Lin S, Zhang Y, Dodel R, Farlaw MR, Paul SM, Du Y (2001) Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315:61–64PubMedCrossRef

24.

Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M (2001) Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103:2181–2187PubMed

25.

Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762–2767PubMed

26.

Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44:2163–2170PubMedCrossRef

27.

Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105–111PubMedCrossRef

28.

Parsons SL, Watsom SA, Broen PD, Collins HM, Steele RJC (1997) Matrix metalloproteinases. Br J Surg 84:160–166PubMedCrossRef

29.

Planas AM, Sole S, Justicia C (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8:834–846PubMedCrossRef

30.

Renner O, Tsimpas A, Kostin S, Valable S, Petit E, Schaper W, Marti HH (2003) Time- and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia. Brain Res Mol Brain Res 113:44–51PubMedCrossRef

31.

Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M (2002) Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15:19–32PubMedCrossRef

32.

Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood brain barrier opening after reperfusion in rat brain. Stroke 29:2189–2195PubMed

33.

Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG (1992) TIMP-2 reduces proteolytic opening of blood brain barrier by type IV collagenase. Brain Res 576:203–207PubMedCrossRef

34.

Rosenberg GA, Navratil M, Barone F, Feuerstein G (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360–366PubMedCrossRef

35.

Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA (2001) Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8:305–316PubMed

36.

Sadowski T, Steinmeyer J (2001) Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 50:175–182PubMedCrossRef

37.

Spinale FG, Coker ML, Bond BR, Zellner JL (2000) Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46:225–238PubMedCrossRef

38.

Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580–2588PubMed

39.

Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527–7533PubMed

40.

Vaday GG, Hershkovitz R, Rahat MA, Lahat N, Cahalon L, Lider O (2000) Fibronectin-bound TNF-α stimulates monocyte matrix metalloproteinase-9 and regulates chemotaxis. J Leukoc Biol 68:737–747PubMed

41.

Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154PubMed

42.

Yano M, Omoto Y, Yamakawa Y, Nakashima Y, Kiriyama M, Saito Y, Fujii Y (2001) Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 20:679–686PubMedCrossRef

43.

Yoo MH, Lee YH, Lee SE, Koh JY, Yoon YH (2004) Protection by pyruvate of rat retinal cells against zinc toxicity in vitro, and pressure-induced ischemia in vivo. Invest Ophthalmol Vis Sci 45:1523–1530PubMedCrossRef

44.

Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MO (2004) Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration. Invest Ophthalmol Vis Sci 45:2753–2759PubMedCrossRef

45.

Zhang X, Sakamoto T, Hata Y, Kubota T, Hisatomi T, Murata T, Ishibashi T, Inomata H (2002) Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res 74:577–584PubMedCrossRef

46.

Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Sarang S, Liu AS, Hart DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Ktistal BS, Friedlander RM (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74–78PubMedCrossRef

Title: The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia
Authors: Nurit Mathalone
Nitza Lahat
Michal A. Rahat
Keren Bahar-Shany
Yoram Oron
Orna Geyer
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-006-0362-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2007

Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy

High incidence of antibodies to lens proteins in sera from patients with uveitis

The effect of ultraviolet radiation on choroidal melanocytes and melanoma cell lines: cell survival and matrix metalloproteinase production

Macular hole surgery complicated by accidental massive subretinal indocyanine green, and retinal tear

Scleral window surgery and topical mitomycin C for nanophthalmic uveal effusion complicated by renal failure: case report

The long-term safety of donor eye for 180 degrees limbal transplantation